FTC weighs in on Teva's inhaler litigation against Amneal amid far-reaching patent crackdown

When it comes to questioning drug patents, the U.S. Federal Trade Commission (FTC) isn’t backing down.

After filing a challenge in November against more than 100 patents in the FDA’s Orange Book—and persuading several drugmakers to retract their intellectual property (IP) protections in the process—the antitrust agency is now calling out uncooperative companies in court.